AbbVie | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Abbott USD 81.45B 34M 2025-03
ALKERMES USD 2.08B 26.41M 2025-03
Amgen USD 89.37B 2.47B 2025-03
AstraZeneca USD 106.25B 2.22B 2025-03
Biogen USD 28.03B 16.2M 2025-03
BioMarin Pharmaceutical USD 7.15B 158.07M 2025-03
Bristol-Myers Squibb USD 92.43B 176M 2025-03
Eisai JPY 1.43T 111.45B 2024-12
Eli Lilly USD 89.39B 10.67B 2025-03
Gilead Sciences USD 56.43B 2.56B 2025-03
GlaxoSmithKline GBP 60.71B 1.24B 2025-03
J&J USD 193.67B 13.57B 2025-03
Medtronic USD 89.97B 69M 2025-01
Merck USD 115.12B 1.98B 2025-03
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pacira USD 1.55B 31.82M 2024-12
Perrigo USD 9.76B 112.1M 2025-03
Pfizer USD 208.03B 5.37B 2025-03
Regeneron Pharmaceuticals USD 37.55B 214.2M 2025-03
Roche Holding CHF 101.8B 6.02B 2024-12
Sanofi 131.89B 906M 2025-03
UCB EUR 17.35B 1.72B 2024-12
Ultragenyx Pharmaceutical USD 1.31B 191.53M 2025-03
United Therapeutics USD 7.74B 379.9M 2025-03
Vertex Pharmaceuticals USD 22.53B 293M 2024-12
Zoetis USD 14.1B 139M 2025-03



AbbVie Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.